BlueGnome Targets IVF Screening Market with New 24Sure Arrays, Service | GenomeWeb

By Justin Petrone

BlueGnome, a Cambridge, UK-based firm that has traditionally sold arrays and software to the neonatal cytogenetics research market, has now begun offering arrays and services for specific use in in vitro fertilization studies, according to a company official.

The new platform, called 24Sure, uses a bacterial artificial chromosome array and software to screen for abnormal or aneuploid chromosomes.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.